Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Oncology Advisory Committee Is Still Pazdur’s Center of Excellence

Executive Summary

Richard Pazdur is moving to a new role in FDA as part of a reorganization driven by the Cancer 'Moonshot.' The most recent Oncologic Drugs Advisory Committee meeting, however, demonstrates that he is still very much in command of cancer drug reviews.

You may also be interested in...



FDA's Pazdur To Retain Drug Approval Duties In Oncology Center Of Excellence

Center for Drug Evaluation and Research's long-time director of oncology/hematology products office will continue as signatory on drug reviews even after new Cancer Moonshot-driven structure takes effect.

Spectrum's Apaziquone Pooled Analysis Can't Make Up For Negative Studies

Faced with two unsuccessful pivotal trials, FDA advisory committee concludes substantial evidence of a treatment effect in non-muscle invasive bladder cancer has not been demonstrated.

FDA's Pazdur Won't Become Oncology Bureaucrat: 'My Presence Will Be Felt'

Richard Pazdur is stepping aside from FDA's Office of Hematology and Oncology Products to head the agency's newly created Oncology Center of Excellence, but he expects to still run twice-weekly group meetings at OHOP.

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel